Management of antidiabetic treatment in an elderly fragile patient with diabetes mellitus

Česká verzia

Authors: Zbynek Schroner ¹; Vladimír Uličiansky ²
Authors place of work: SchronerMED s. r. o., Košice, 2Via Medica, s. r. o., Košice ¹
Published in the journal: Diab Obez 2020; 20(39): 35-41
Category: Reviews

Summary

In 2018 in Slovakia 355 895 patients with diabetes mellitus were registered, almost 200 000 were older than 60 years. Suitable antidiabetic drug for older, fragile patients should be: cardiovascular safe, associated with low risk of hypoglycaemia, renal and oncologic safe, should have simple method of administration and anticipating general safety profile. Key for success also in older, fragile patient is individualisation of therapy. Proper selection of patient for every antidiabetic treatment is necessary. DPP-4 inhibitors are good option for the therapy of older, fragile patient with type 2 diabetes mellitus.

Keywords:

antidiabetic therapy – older fragile patient – type 2 diabetes mellitus

Zdroje

Činnosť diabetologických ambulancií v SR 2016. NCZI Bratislava 2017; ZŠ 11–2017. ISBN 978–80–89292–30–1. Dostupné z WWW: <http://www.nczisk.sk/Documents/publikacie/2016/zs1711.pdf>.
Older Adults: Standards of Medical Care in Diabetes-2020. Diabetes Care 2020; 43(Suppl 1): S152-S162. Dostupné z DOI: <http://dx.doi.org/10.2337/dc20-S012>.
LeRoith D, Biessels GJ, Braithwaite SS et.al. Treatment of diabetes in older adults: an endocrine society. Clinical practice guideline. J Clin Endocrinol Metab 2019; 104(5): 1520–1574. Dostupné z DOI: <http://dx.doi.org/10.1210/jc.2019–00198>.
Uličiansky V, Schroner Z, Galajda P et al. Diabetes v zrelom veku. QuickPrint: Martin 2013: 149–169. ISBN 978–80–971417–1-4.
Schroner Z, Haluzík M, Mráz M et al. Antidiabetiká a kardiovaskulárne riziko. SchronerMED: Košice 2017. ISBN 978–80–8129–073–2.
White WB, Cannon CP, Heller SR et al. Alogliptin after acute coronary syndromes in patients with type 2 diabetes. N Engl J Med 2013; 369(4): 1327–1335. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1305889>.
Scirica BM, Bhatt DL, Braunwald E et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369(14): 1317–1326. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1307684>.
Green JB, Bethel MA, Armstrong PW et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2015; 373(3): 232–242. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1501352>.
Rosenstock J, Perkovic V, Johansen OE et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk. The CARMELINA randomized clinical trial. JAMA 2019; 321(1): 69–79. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2018.18269>.
Marso SP, Daniels GH, Brown-Frandsen K et al. Liraglutide a cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375(4): 311–322. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1603827>.
Marso SP, Bain SC, Consoli A et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375(19); 1834–1844. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1607141>.
Gerstein HC, Colhoun HM, Dagenais GR et al. Dulaglutid and cardiovascular outcomes in type 2 diabetes (REWIND): a double blind, randomized placebo controlled trial. Lancet 2019; 394(10193): 121–130. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(19)31149–3>.
Pfeffer MA, Claggett B, Diaz R et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015; 373(23): 2247–2257. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1509225>.
Zinman B, Wanner C, Lachin JM et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373(22): 2117–2128. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1504720>.
Neal B, Perkovic V, Mahaffey KW et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377(7): 644–657. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1611925>.
Wiviott SD, Raz I, Bonaca P et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Eng J Med 2019; 380(4): 347–357. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1812389>.
Perkovic V, Jardine MJ, Neal B et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380(24): 2295–2306. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1811744>.
Davies MJ, D Alessio DA, Fradkin J et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018; 61(12): 2461–2498. Dostupné z DOI: <https://doi.org/10.1007/s00125–018–4729–5>.
Martinka M, Uličiansky BV, Mokáň M et al. Konsenzuálne terapeutické odporúčanie Slovenskej diabetologickej spoločnosti pre diabetes mellitus 2. typu (2018). Forum Diab 2018; 7(1): 47–68.
Johansen OE. Interpretation of cardiovascular outcome trials in type 2 diabetes needs a multiaxial approach. World J Diabetes 2015; 6(9): 1092–1096. Dostupné z DOI: <https://doi: 10.4239/wjd.v6.i9.1092>.